Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Bioavailability of [14C]-SK-1404 ADME & IV Microtracer Study

12 octobre 2016 mis à jour par: Sanwa Kagaku Kenkyusho Co., Ltd.

An Open-Label, 2-Part Sequential Dose Study Designed to Assess the Absolute Bioavailability, Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]-SK-1404 Administered to Healthy Male Subjects

The primary objectives of the study are:

  • To determine the absolute bioavailability of SK-1404
  • To assess the mass balance recovery after a single oral (PO) dose of carbon-14 (14C)-SK-1404
  • To provide plasma, urine and faecal samples for metabolite profiling and structural identification

The secondary objectives of the study are:

  • To determine the routes and rates of elimination of [14C]-SK-1404
  • To identify the chemical structure of each metabolite with an exposure (AUC) of more than 10% of circulating total radioactivity
  • To explore the intravenous (IV) pharmacokinetics (PK) of [14C]-SK-1404
  • To further explore the PO PK of SK-1404
  • To provide additional safety and tolerability information for SK-1404

Aperçu de l'étude

Statut

Complété

Les conditions

Intervention / Traitement

Description détaillée

This is a single-centre, 2-part, open-label, non-randomised, sequential, single dose study in healthy male subjects. It is planned to enrol a single cohort of 6 healthy male subjects who will participate in Parts 1 and Part 2 of the study.

In Part 1, each subject will receive a single PO dose of SK-1404 followed by an IV microtracer dose of [14C]-SK-1404.

In Part 2, each subject will receive a single PO dose of [14C]-SK-1404.

Type d'étude

Interventionnel

Inscription (Réel)

6

Phase

  • La phase 1

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Lieux d'étude

    • Nottingham
      • Ruddington, Nottingham, Royaume-Uni, NG11 6JS
        • Quotient Clinical

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

30 ans à 65 ans (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Oui

Sexes éligibles pour l'étude

Homme

La description

Inclusion Criteria:

  1. Healthy males
  2. Age 30 to 65 years of age
  3. Body mass index of 18.0 to 35.0 kg/m2 or, if outside the range, considered not clinically significant by the investigator
  4. Must be willing and able to communicate and participate in the whole study
  5. Must provide written informed consent
  6. Must have regular bowel movements (ie average stool production of ≥1 and ≤3 stools per day)
  7. Must agree to use an adequate method of contraception

Exclusion Criteria:

  1. Males with pregnant partners
  2. Participation in a clinical research study within the 3 months prior to IMP dose
  3. Subjects who are study site employees, or immediate family members of a study site or sponsor employee
  4. Subjects who have previously been enrolled in this study
  5. Subjects who have previously been dosed with SK-1404
  6. History of any drug or alcohol abuse in the past 2 years
  7. Regular alcohol consumption in males >21 units per week (1 unit = ½ pint beer, 25 mL of 40% spirit or a 125 mL glass of wine) in the past year
  8. Current smokers and those who have smoked within the last 12 months; this includes cigarettes, e-cigarettes and nicotine replacement products. A breath carbon monoxide reading of greater than 10 ppm at screening or admission
  9. Radiation exposure, including that from the present study, excluding background radiation but including diagnostic x-rays and other medical exposures, exceeding 5 mSv in the last 12 months or 10 mSv in the last 5 years. No occupationally exposed worker, as defined in the Ionising Radiation Regulations 1999, shall participate in the study
  10. Subjects who have been enrolled in an ADME study in the last 12 months
  11. Subjects who do not have suitable veins for multiple venepunctures/cannulation as assessed by the investigator at screening
  12. Clinically significant abnormal biochemistry, haematology or urinalysis as judged by the investigator (laboratory parameters are listed in Appendix 1)
  13. Aspartate aminotransferase, alanine aminotransferase or alkaline phosphatase >1.5 × upper limit of normal confirmed by repeat testing
  14. Serum sodium below the lower limit of normal

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Science basique
  • Répartition: N / A
  • Modèle interventionnel: Affectation à un seul groupe
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: [14C]-SK-1404
In Part 1, each subject will receive a single PO dose of SK-1404 followed by an IV microtracer dose of [14C]-SK-1404.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Absolute bioavailability (F) calculated with the AUC values of IV administration in Part 1 and PO administration in Part 2
Délai: Predose to 96hr
Predose to 96hr
Mass balance recovery of total radioactivity in urine, faeces and all excreta
Délai: Predose to 168hr
Amount excreted (Ae), and Ae as a percentage of the administered dose (%Ae), cumulative recovery (Cum Ae) and cumulative recovery expressed as a percentage of the dose (Cum %Ae)
Predose to 168hr
Number and structural identification of known and unknown metabolites of SK-1404 in the plasma, urine and faeces samples
Délai: Predose to 168hr
Predose to 168hr

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Ae total radioactivity in plasma by metabolite profiling and structural identification to estimate the routes and rates of elimination of [14C]-SK-1404
Délai: Predose to 168hr
Predose to 168hr
%Ae total radioactivity in plasma by metabolite profiling and structural identification to estimate the routes and rates of elimination of [14C]-SK-1404
Délai: Predose to 168hr
Predose to 168hr
Cum Ae (total) for urine by metabolite profiling and structural identification to estimate the routes and rates of elimination of [14C]-SK-1404
Délai: Predose to 168hr
Predose to 168hr
Cum %Ae (total) for urine by metabolite profiling and structural identification to estimate the routes and rates of elimination of [14C]-SK-1404
Délai: Predose to 168hr
Predose to 168hr
Cum Ae (total) for faeces by metabolite profiling and structural identification to estimate the routes and rates of elimination of [14C]-SK-1404
Délai: Predose to 168hr
Predose to 168hr
Cum %Ae (total) for faeces by metabolite profiling and structural identification to estimate the routes and rates of elimination of [14C]-SK-1404
Délai: Predose to 168hr
Predose to 168hr
Number and structural identification of unknown metabolites of SK-1404 with an AUC of more than 10% of circulating total radioactivity
Délai: Predose to 168hr
Predose to 168hr
The peak plasma concentration (Cmax) of SK-1404F and its active metabolites M-1, M-7 and M-9) after IV SK-1404
Délai: Predose to 96hr
Metabolite:parent ratios will be calculated for SK-1404F, M-1, M-7 and M-9
Predose to 96hr
The time from dosing at which Cmax was apparent (Tmax) of SK-1404F and its active metabolites M-1, M-7 and M-9) after IV SK-1404
Délai: Predose to 96hr
Metabolite:parent ratios will be calculated for SK-1404F, M-1, M-7 and M-9
Predose to 96hr
The elapsed time from dosing at which the analyte was first quantifiable in a concentration vs time profile (Tlag) of SK-1404F and its active metabolites M-1, M-7 and M-9) after IV SK-1404
Délai: Predose to 96hr
Metabolite:parent ratios will be calculated for SK-1404F, M-1, M-7 and M-9
Predose to 96hr
The area under the concentration-time curve from dosing to the last measurable concentration (AUC(0-last)) of SK-1404F and its active metabolites M-1, M-7 and M-9) after IV SK-1404
Délai: Predose to 96hr
Metabolite:parent ratios will be calculated for SK-1404F, M-1, M-7 and M-9
Predose to 96hr
The area under the concentration-time curve from dosing extrapolated to infinity (AUC(0-inf)) of SK-1404F and its active metabolites M-1, M-7 and M-9) after IV SK-1404
Délai: Predose to 96hr
Metabolite:parent ratios will be calculated for SK-1404F, M-1, M-7 and M-9
Predose to 96hr
The percentage of AUC(0-inf) extrapolated beyond the last measured time point (AUC%extrap) of SK-1404F and its active metabolites M-1, M-7 and M-9) after IV SK-1404
Délai: Predose to 96hr
Metabolite:parent ratios will be calculated for SK-1404F, M-1, M-7 and M-9
Predose to 96hr
The terminal elimination rate constant calculated from the slope of the apparent elimination phase (lambda-z) of SK-1404F and its active metabolites M-1, M-7 and M-9) after IV SK-1404
Délai: Predose to 96hr
Metabolite:parent ratios will be calculated for SK-1404F, M-1, M-7 and M-9
Predose to 96hr
The apparent terminal elimination half-life (T1/2) of SK-1404F and its active metabolites M-1, M-7 and M-9) after IV SK-1404
Délai: Predose to 96hr
Metabolite:parent ratios will be calculated for SK-1404F, M-1, M-7 and M-9
Predose to 96hr
The apparent total clearance (CL/F) of SK-1404F and its active metabolites M-1, M-7 and M-9) after IV SK-1404
Délai: Predose to 96hr
Metabolite:parent ratios will be calculated for SK-1404F, M-1, M-7 and M-9
Predose to 96hr
The apparent volume of distribution (Vd) of SK-1404F and its active metabolites M-1, M-7 and M-9) after IV SK-1404
Délai: Predose to 96hr
Metabolite:parent ratios will be calculated for SK-1404F, M-1, M-7 and M-9
Predose to 96hr
The apparent volume of distribution (Vss) of SK-1404F and its active metabolites M-1, M-7 and M-9) after IV SK-1404
Délai: Predose to 96hr
Metabolite:parent ratios will be calculated for SK-1404F, M-1, M-7 and M-9
Predose to 96hr
The mean residence time (MRT) of SK-1404F and its active metabolites M-1, M-7 and M-9) after IV SK-1404
Délai: Predose to 96hr
Metabolite:parent ratios will be calculated for SK-1404F, M-1, M-7 and M-9
Predose to 96hr
The peak plasma concentration (Cmax) of SK-1404F and its active metabolites M-1, M-7 and M-9) after PO SK-1404
Délai: Predose to 168hr
Metabolite:parent ratios will be calculated for SK-1404F, M-1, M-7 and M-9
Predose to 168hr
The time from dosing at which Cmax was apparent (Tmax) of SK-1404F and its active metabolites M-1, M-7 and M-9) after PO SK-1404
Délai: Predose to 168hr
Metabolite:parent ratios will be calculated for SK-1404F, M-1, M-7 and M-9
Predose to 168hr
The elapsed time from dosing at which the analyte was first quantifiable in a concentration vs time profile (Tlag) of SK-1404F and its active metabolites M-1, M-7 and M-9) after PO SK-1404
Délai: Predose to 168hr
Metabolite:parent ratios will be calculated for SK-1404F, M-1, M-7 and M-9
Predose to 168hr
The area under the concentration-time curve from dosing to the last measurable concentration (AUC(0-last)) of SK-1404F and its active metabolites M-1, M-7 and M-9) after PO SK-1404
Délai: Predose to 168hr
Metabolite:parent ratios will be calculated for SK-1404F, M-1, M-7 and M-9
Predose to 168hr
The area under the concentration-time curve from dosing extrapolated to infinity (AUC(0-inf)) of SK-1404F and its active metabolites M-1, M-7 and M-9) after PO SK-1404
Délai: Predose to 168hr
Metabolite:parent ratios will be calculated for SK-1404F, M-1, M-7 and M-9
Predose to 168hr
The percentage of AUC(0-inf) extrapolated beyond the last measured time point (AUC%extrap) of SK-1404F and its active metabolites M-1, M-7 and M-9) after PO SK-1404
Délai: Predose to 168hr
Metabolite:parent ratios will be calculated for SK-1404F, M-1, M-7 and M-9
Predose to 168hr
The terminal elimination rate constant calculated from the slope of the apparent elimination phase (lambda-z) of SK-1404F and its active metabolites M-1, M-7 and M-9) after PO SK-1404
Délai: Predose to 168hr
Metabolite:parent ratios will be calculated for SK-1404F, M-1, M-7 and M-9
Predose to 168hr
The apparent terminal elimination half-life (T1/2) of SK-1404F and its active metabolites M-1, M-7 and M-9) after PO SK-1404
Délai: Predose to 168hr
Metabolite:parent ratios will be calculated for SK-1404F, M-1, M-7 and M-9
Predose to 168hr
The absolute bioavailability (F, PO vs IV from Part 1) of SK-1404F and its active metabolites M-1, M-7 and M-9) after PO SK-1404
Délai: Predose to 168hr
Metabolite:parent ratios will be calculated for SK-1404F, M-1, M-7 and M-9
Predose to 168hr
The apparent total clearance (CL/F) of SK-1404F and its active metabolites M-1, M-7 and M-9) after PO SK-1404
Délai: Predose to 168hr
Metabolite:parent ratios will be calculated for SK-1404F, M-1, M-7 and M-9
Predose to 168hr
The apparent volume of distribution (Vd/F) of SK-1404F and its active metabolites M-1, M-7 and M-9) after PO SK-1404
Délai: Predose to 168hr
Metabolite:parent ratios will be calculated for SK-1404F, M-1, M-7 and M-9
Predose to 168hr
The mean residence time (MRT) of SK-1404F and its active metabolites M-1, M-7 and M-9) after PO SK-1404
Délai: Predose to 168hr
Metabolite:parent ratios will be calculated for SK-1404F, M-1, M-7 and M-9
Predose to 168hr
To collect further information about the safety and tolerability of IMP
Délai: Predose to 168hr
By assessing physical examination, safety laboratory tests, vital signs, electrocardiograms (ECGs) and AEs.
Predose to 168hr

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Les enquêteurs

  • Chercheur principal: Litza McKenzie, MBChB BScMedSci, Quotient Clinical

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude

1 juillet 2016

Achèvement primaire (Réel)

1 août 2016

Achèvement de l'étude (Réel)

1 août 2016

Dates d'inscription aux études

Première soumission

5 août 2016

Première soumission répondant aux critères de contrôle qualité

19 août 2016

Première publication (Estimation)

25 août 2016

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Estimation)

14 octobre 2016

Dernière mise à jour soumise répondant aux critères de contrôle qualité

12 octobre 2016

Dernière vérification

1 octobre 2016

Plus d'information

Termes liés à cette étude

Mots clés

Autres numéros d'identification d'étude

  • QCL117764

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

NON

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

Essais cliniques sur [14C]-SK-1404

3
S'abonner